Welcome to our dedicated page for TRPXY news (Ticker: TRPXY), a resource for investors and traders seeking the latest updates and insights on TRPXY stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TRPXY's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TRPXY's position in the market.
SciSparc Ltd. (OTCQB: TRPXY), a clinical-stage pharmaceutical firm, announced a partnership with Procaps for the development and commercial production of its drug candidate, SCI-110, and CannAmide™ in softgel form. CannAmide, an oral formulation for chronic pain relief, has gained Health Canada approval. SCI-110, combining CannAmide and THC, targets central nervous system diseases, initially focusing on Tourette syndrome. The collaboration aims to enhance efficacy and safety through a randomized trial, building on positive results from previous studies.
SciSparc Ltd. (OTCQB: TRPXY) has commenced commercial production of CannAmide™, a proprietary oral tablet formulation containing Palmitoylethanolamide (PEA), targeting chronic pain relief. This innovative product will be distributed to pharmacies across Canada following a new distribution agreement. Chronic pain affects over 100 million Americans and costs approximately $600 billion annually. CannAmide™ is positioned as a safer alternative to opioids, which generate around $20 billion in revenue but contribute to addiction issues. The CEO expresses optimism about future pharmaceutical developments and market potential.
